Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Lenvatinib and Chemotherapy in First Line ES-SCLC
NCT05384015Phase 2Active, not recruiting
- Sponsor
- Fundación GECP
- Start
- Nov 2022
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in small cell lung cancer (SCLC), sponsored by Fundación GECP. Started Nov 2022; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05384015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384015.